Mirum Pharmaceuticals D
D
MIRM
94.020
USD
0.72
(0.77%)
Market Closed
Last updated: · Delayed 15 min
Volume
9,110
EPSWhat is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
-16
Div YieldWhat is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
-
P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
-6
Market CapWhat is market capitalization? Market cap is what the stock market values a whole company at: its share price times the number of its shares outstanding.
6,137,817,777
Title: Mirum Pharmaceuticals
Sector: Healthcare
Industry: Biotechnology
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.